The T1D Fund Overview
In 2016, a group of JDRF volunteers identified that a lack of life sciences venture capital investment in type 1 diabetes (T1D) was one of the biggest roadblocks to progress toward a cure. To overcome that obstacle, JDRF created the T1D Fund – a combination of venture capital and philanthropy focused solely on accelerating the development of commercial products and therapies for T1D.
Curing disease demands the cooperation of a mosaic of constituents. Five years ago, we were missing a critical piece of the puzzle.
When donors back this fund, their investments support companies with a focus on drugs, devices, diagnostic tools and other health solutions with applications to T1D. The T1D Fund chooses companies that can make the greatest clinical impact on T1D – leading to better disease management and potential cures.
The T1D Fund is now the largest single-disease focused venture philanthropy fund in the world. In just four years, our Fund and its alongside venture capital have invested an incredible $500 million in T1D programs. The number of companies working on T1D therapies has grown from just a handful to more than 30 pharmaceutical and biotech companies – backed by more than 85 donors worldwide and 30+ venture capital and biotech funders. It has also led to several exciting developments in T1D and major acquisitions of T1D Fund-backed startups.
Previous Page
Next Page
